Regeneron Pharmaceuticals
REGN
1,310 hedge funds and large institutions have $89.2B invested in Regeneron Pharmaceuticals in 2024 Q1 according to their latest regulatory filings, with 147 funds opening new positions, 481 increasing their positions, 452 reducing their positions, and 95 closing their positions.
55% more first-time investments, than exits
New positions opened: 147 | Existing positions closed: 95
10% more capital invested
Capital invested by funds: $81.4B → $89.2B (+$7.84B)
3% more funds holding
Funds holding: 1,273 → 1,310 (+37)
6% more repeat investments, than reductions
Existing positions increased: 481 | Existing positions reduced: 452
0% more funds holding in top 10
Funds holding in top 10: 25 → 25 (0)
0.15% less ownership
Funds ownership: 86.44% → 86.29% (-0.15%)
40% less call options, than puts
Call options by funds: $971M | Put options by funds: $1.63B
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Franklin Resources
San Mateo,
California
|
+$1.15B |
| 2 |
JP Morgan Chase
New York
|
+$476M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$453M |
| 4 |
GAA
Global Assets Advisory
Orlando,
Florida
|
+$335M |
| 5 |
Massachusetts Financial Services
Boston,
Massachusetts
|
+$226M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$893M |
| 2 |
Capital World Investors
Los Angeles,
California
|
-$452M |
| 3 |
Holocene Advisors
New York
|
-$265M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$196M |
| 5 |
D.E. Shaw & Co
New York
|
-$127M |
REGN Hedge Fund Activity: Q1 2024 in Review
1,310 of the 6,943 institutional investors tracked by Wall St. Rank reported a position in Regeneron Pharmaceuticals (REGN) for Q1 2024, worth a combined $89.2B — up 9.6% from $81.4B a quarter earlier.
Buyers outnumbered sellers: 147 funds opened new REGN positions and 95 closed out — a net gain of 52 holders — while 481 added to existing stakes and 452 trimmed.
The largest buyer was Franklin Resources, adding an estimated $1.15B. The largest seller was Morgan Stanley, cutting an estimated $893M.
- 1,310 institutional investors held Regeneron Pharmaceuticals (REGN) as of Q1 2024, up from 1,273 in Q4 2023.
- Funds reported $89.2B of Regeneron Pharmaceuticals stock for Q1 2024, up 9.6% quarter-over-quarter.
- 147 funds opened new Regeneron Pharmaceuticals positions in Q1 2024 and 95 closed out, a net change of +52 holders.
- The largest Regeneron Pharmaceuticals buyer in Q1 2024 was Franklin Resources, an estimated $1.15B added.
- The largest Regeneron Pharmaceuticals seller in Q1 2024 was Morgan Stanley, an estimated $893M sold.
Based on aggregated 13F filings for Q1 2024.